Precision Oncology in Practice: Scaling Personalized Cancer Care Through Genomics, ctDNA, and Systemwide Integration
核心洞察
Precision oncology has moved from research into routine clinical practice, reshaping risk assessment, treatment selection, and recurrence monitoring through genomic insights.
Circulating tumor DNA (ctDNA) and molecular residual disease (MRD) testing are redefining early-stage cancer (搜索) management by enabling real-time disease assessment without radiographic findings.
Health systems face operational challenges including standardization of clinical pathways, EHR integration, and the need for molecular tumor boards to scale precision oncology effectively.
Personalized cancer (搜索) care — where therapies are tailored to the genomic makeup of a patient and their tumor — is no longer a futuristic concept. It is now a reality. Precision oncology has moved from the research setting into routine clinical practice, reshaping how clinicians assess risk, select treatments, and monitor for recurrence. But translating that promise into consistent, systemwide results demands close collaboration among clinicians, health systems, researchers, technology partners, and industry.
"Precision oncology enables personalized cancer (搜索) care and is achieved through genomics," said Minetta Liu, MD, chief medical officer of oncology and early cancer detection at Natera, in a conversation with Becker's Healthcare. "Germline genetic testing determines hereditary cancer risk so that patients and their families can consider more intensive, but focused, screening programs. Genomic tumor profiling, on the other hand, can identify treatment opportunities tailored to the specific biology of a given cancer."
The Role of Circulating Tumor DNA and MRD Testing
One of the most transformative developments in precision oncology is the use of circulating tumor DNA (ctDNA) analysis to detect molecular residual disease (MRD). In the absence of radiographic findings, this technology supports longitudinal monitoring at the molecular level to facilitate timely intervention and treatment optimization. In some cases, it reduces unnecessary therapy exposure.
"Assessing disease status in real time through serial ctDNA testing of the peripheral blood is redefining the management of early-stage cancer (搜索)," Dr. Liu explained. "It provides a quantifiable tumor measurement in the absence of clinical or radiographic findings."
Natera has been at the forefront of generating data supporting MRD detection across three critical activities: prognostication, treatment response monitoring, and surveillance for cancer (搜索) recurrence. MRD detection serves as a powerful prognostic factor, enabling clinicians to tailor adjuvant treatment based on recurrence risk. For dynamic treatment response monitoring, MRD provides a reliable tool to ensure current therapy is effective. In active surveillance, MRD detection can identify recurrence earlier, when a "second chance" at cure is possible.
Operationalizing Precision Oncology Across Health Systems
Despite the clinical promise, maturity varies significantly between organizations. Operational challenges to effective implementation include standardization of clinical pathways, the availability of embedded genomic workflows and molecular tumor boards, and EHR integration.
"The key to operationalizing precision oncology in clinical practice is integrating genomic testing into clinical workflows," Dr. Liu noted. "Parallel systems for 'specialty tests' increase burden on clinicians and staff. This applies to orders, biospecimen collection and shipment, and return of results."
Health systems should focus on standardization and clinical decision support. Providers do not have time to navigate a multitude of different testing options or manually interpret complex genomic reports. Embedding evidence-based guidance directly into the EHR, creating streamlined ordering pathways, and leveraging multidisciplinary support teams are essential. This requires cross-functional support from genetics, pathology, pharmacy, informatics, nursing, navigation, and operations — all working together as a coordinated system.
Successful, systemwide implementation in community practices requires an enterprise strategy approach, including governance structures, evidence-based clinical pathways, investment in informatics infrastructure, and shared accountability across departments. Standardized test menus, strong EHR integration, and centralized genomic review processes like molecular tumor boards are critical for operational sustainability.
Targeted Therapies and the Next Wave of Innovation
Precision medicine flips the traditional script. Instead of treating cancer (搜索) by its location, it treats the patient's specific biological blueprint. Targeted therapies operate more like a lock and key, targeting the exact molecular pathways that drive disease while leaving healthy cells alone. This stands in stark contrast to traditional chemotherapy, which kills all fast-growing cells and results in collateral damage to healthy tissue.
The impact on patient outcomes is significant. When the root cause of a tumor is targeted immediately, response rates improve, patients receive the right medicine the first time, and overall toxicity is lower — allowing patients to maintain a better quality of life during treatment.
Among the most notable breakthroughs is progress against previously "undruggable" targets. The KRAS (搜索) gene mutation, a notorious driver of some of the most aggressive and hard-to-treat cancers, baffled researchers for thirty years and defeated every drug thrown at it. Now, investigational therapies like Zoldonrasib are leading the charge to finally break through KRAS-driven defenses. Patients who once ran out of options may soon have entirely new treatment possibilities.
Barriers to Broader Adoption
Broader adoption of ctDNA testing for MRD detection requires ongoing prospective evidence generation, clearer alignment with practice guidelines, stronger reimbursement pathways, and seamless integration into clinical workflows. Clinicians need confidence in operationalizing these tools across large patient populations.
Access and affordability remain significant roadblocks. Genomic sequencing and custom-built drugs require massive high-tech infrastructure, making them incredibly expensive. Healthcare systems, insurance providers, and drug developers are racing to discover ways to scale down production costs.
The Future of Precision Oncology
Looking ahead, Dr. Liu expressed excitement about moving beyond targeted therapy for metastatic disease to continuous reassessment of a tumor's biology, adapting care and administering therapy when it is clinically meaningful. "The standard of care in oncology is advancing with the advent of multimodal testing approaches and big data capabilities. The next frontier will be expanding cancer (搜索) screening to all cancer types and improving access to care through blood-based testing, rather than procedure-based testing."
Over time, ctDNA testing will increasingly help guide treatment optimization, surveillance intensity, and clinical trial enrollment. The convergence of big data, biology, and computer science is also opening new career paths in clinical research, genetic counseling, and bioinformatics, as global collaboration among researchers, universities, healthcare institutions, and biotechnology organizations continues to drive medical innovation forward.